- Conditions
- Alzheimer Disease, Agitation
- Interventions
- KarXT, KarX-EC
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 44
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1945–1968
of 13,086
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
- Biological · Drug · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more
- Conditions
- Sepsis
- Interventions
- PRESS Intervention
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 984 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri
- Conditions
- Migraine Disorders
- Interventions
- sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 49
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Inhaled human insulin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 29
- States / cities
- Burlingame, California • Irvine, California • Newport Beach, California + 26 more
- Conditions
- Schizophrenia
- Interventions
- Luvadaxistat, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Garden Grove, California • Lemon Grove, California • Los Angeles, California + 13 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-445/TEZ/IVA, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 53
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more
- Conditions
- End-Stage Renal Disease
- Interventions
- Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 20 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Craniosynostosis
- Interventions
- neurobehavioral development
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 2 Months to 7 Years
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2015
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Westchester, Illinois • St Louis, Missouri + 1 more
- Conditions
- Heart Failure
- Interventions
- Tolvaptan or Samsca, placebo or sugar pill
- Drug
- Lead sponsor
- Cardiovascular Clinical Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 34 more
- Conditions
- Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Radiation · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2031
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Gainesville, Florida + 17 more
- Conditions
- Low Grade Glioma
- Interventions
- Vinblastine, Bevacizumab
- Drug
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- IBI3003
- Drug
- Lead sponsor
- Fortvita Biologics (USA)Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 3 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Crohn's Disease
- Interventions
- natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Oceanside, California • San Francisco, California + 31 more
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- Eteplirsen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 13 Years · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia
- Conditions
- Multiple Myeloma, Relapsed Refractory Multiple Myeloma
- Interventions
- Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- REGN7508, Apixaban, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 66
- States / cities
- Alexander City, Alabama • Dothan, Alabama • Fairhope, Alabama + 57 more
- Conditions
- Cancer
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 50,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1995 – 2026
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 23 more
- Conditions
- Emphysema, COPD
- Interventions
- IBV® Valve System
- Device
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- 40 Years to 74 Years
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mission Viejo, California + 29 more
- Conditions
- Multiple Sclerosis
- Interventions
- CDP323, placebo
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 22
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
- Conditions
- Thyroid Neoplasms
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Other Multikinase inhibitors
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Torrance, California + 13 more
- Conditions
- Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, Blast Crisis
- Interventions
- XmAb14045
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 9
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more